Stay Up to Date
Breaking News,
Updates, & More
Click Here to

Use of Ibrutinib May Replace ASCT in Mantle-Cell Lymphoma

TOP - March 2023 Vol 16, No 2 - Hematologic Malignancies, Lymphoma

Ibrutinib (Imbruvica) may allow patients with newly diagnosed mantle-cell lymphoma (MCL) to forego autologous stem-cell transplantation (ASCT), according to results of the 3-arm randomized TRIANGLE clinical trial presented at the 64th American Society of Hematology Annual Meeting and Exposition. The addition of ibrutinib to ASCT improved failure-free survival (FFS) by 16% compared with ASCT alone. In addition, no difference in FFS was observed at the 3-year time point when ibrutinib was added to ASCT or given as a substitute for ASCT. These data are poised to be practice-changing, but longer follow-up is needed.

“Based on our findings, standard chemotherapy plus ibrutinib [with or without ASCT] is the new standard of care for first-line MCL patients,” said Martin Dreyling, MD, Professor of Medicine, and Head of the Lymphoma Program, Medical Clinic III, Groβhadern Clinic, Ludwig-Maximilians-Universität, Munich, Germany. “We have to wait for the full results; so far, we don’t see any difference between these two ibrutinib curves for progression-free survival and overall survival, but already both curves are numerically superior to the old standard, autologous transplant only.”

“I think clinicians will interpret these results as suggesting you may essentially substitute autologous transplant with ibrutinib to avoid its well-known long-term toxicities,” Dr Dreyling added. “In my opinion, we have to move on.”

MCL is a heterogeneous hematologic malignancy that can be indolent or aggressive. It is frequently diagnosed at a later stage, conferring a poor prognosis. For more than 2 decades, ASCT has been the cornerstone of therapy for previously untreated MCL. In the United States, the current standard of care is high-dose cytarabine-containing chemoimmunotherapy followed by ASCT with rituximab (Rituxan) maintenance.

Study Details

The TRIANGLE study randomized 870 previously untreated patients with MCL to 1 of 3 treatment arms:

  • Control arm: standard-of-care induction chemoimmunotherapy (high-dose cytarabine-containing chemoimmunotherapy followed by ASCT and rituximab maintenance);
  • Induction chemoimmunotherapy plus ibrutinib and ASCT followed by 2 years of ibrutinib maintenance; or
  • Induction chemoimmunotherapy with ibrutinib followed by 2 years of ibrutinib maintenance.

The study was amended to include rituximab maintenance in all 3 arms.

Patients enrolled in the trial had stage II to IV MCL and were aged ≤65 years. Median age was 57 years.

At a median follow-up of 31 months, the addition of ibrutinib to ASCT led to superior FFS versus ASCT (primary end point of the trial). Three-year FFS was 88% in the ibrutinib-containing arm versus 72% without ibrutinib, reflecting a statistically significant 48% reduction favoring ibrutinib (P = .008). Median FFS was not reached in either arm.

“The absolute of disease freedom at 3 years is 16% and highly significant,” Dr Dreyling noted.

The head-to-head comparison of ibrutinib versus ASCT demonstrated numerically higher 3-year FFS for ibrutinib: 86% versus 72% for ASCT. Ibrutinib was noninferior to the current standard of ASCT after chemoimmunotherapy.

“We can only justify ASCT if there is a significant improvement in efficacy. This comparison showed the superiority of ibrutinib, with a numerical benefit of 14% in three-year failure-free survival,” he said.

In the third comparison, no difference was seen between ibrutinib with ASCT and ibrutinib substituted for ASCT, but longer follow-up is needed, Dr Dreyling noted.

There was no major difference between the 2 ASCT-containing arms in the incidence of grade 3 to 5 adverse events (AEs), with the most common events being neutropenia, febrile neutropenia, leukopenia, and infection. In the comparison between ibrutinib plus ASCT versus ibrutinib as a substitute for ASCT, more grade ≥3 AEs were observed during maintenance with the combination of ASCT and ibrutinib.

In the maintenance phase of treatment, higher rates of AEs were observed with standard of care plus ibrutinib compared with either standard of care or ibrutinib alone.

“This suggests that ibrutinib may have optimal use as a replacement for, rather than an addition to, ASCT. Even from the perspective of toxicity, the ideal regimen is a combination of conventional chemotherapy plus ibrutinib,” stated Dr Dreyling.

Expert Commentary

At a press conference during the meeting, moderator Mikkael A. Sekeres, MD, MS, Chief and Professor, Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, FL, said, “This is one of the abstracts that challenge standard of care and suggest that it is possible to give less therapy to patients, reducing the burden of care and improving quality of life. This study suggests that some patients with mantle-cell lymphoma may be able to skip stem-cell transplantation altogether thanks to the targeted drug ibrutinib.”

Related Items
Partnering With Patients to Improve Healthcare Outcomes
Patricia Stewart
TOP - July 2023 Vol 16, No 4 – Online Only published on July 17, 2023 in ASCO 2023 Highlights
Adding Ribociclib to Endocrine Therapy May Reduce Risk for Recurrence in HR-Positive, HER2-Negative, Early Breast Cancer
Patricia Stewart
TOP - July 2023 Vol 16, No 4 – Online Only published on July 17, 2023 in ASCO 2023 Highlights, Breast Cancer
First-Line Luspatercept Increases Likelihood of Transfusion Independence in Patients With Lower-Risk MDS
Patricia Stewart
TOP - July 2023 Vol 16, No 4 – Online Only published on July 17, 2023 in ASCO 2023 Highlights, Hematologic Malignancies
Investigational mRNA-Based Vaccine May Offer New Hope for Patients With High-Risk Melanoma
Patricia Stewart
TOP - July 2023 Vol 16, No 4 – Online Only published on June 12, 2023 in Emerging Therapies, Melanoma, Skin Cancer, AACR Highlights
Public Awareness of the Link Between HPV and Certain Cancers Is Declining Over Time
Patricia Stewart
TOP - May 2023 Vol 16, No 3 published on May 15, 2023 in Cervical Cancer
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
William King
TOP - May 2023 Vol 16, No 3 published on May 5, 2023 in NCCN 2023 Conference Highlights, Lymphoma, Leukemia
Pausing Endocrine Therapy to Become Pregnant Appears Safe for Women with Breast Cancer
Patricia Stewart
TOP - March 2023 Vol 16, No 2 published on March 14, 2023 in Breast Cancer, SABCS
Female Patients Undergoing Cancer Treatment Rarely Asked About Sexual Health
Patricia Stewart
TOP - March 2023 Vol 16, No 2 published on February 22, 2023 in Healthcare Equity, ASTRO Highlights
Improved OS with First-Line Brentuximab Vedotin plus AVD in Advanced Hodgkin Lymphoma
Patricia Stewart
TOP - March 2023 Vol 16, No 2 published on February 22, 2023 in Hematologic Malignancies, Lymphoma
Zanubrutinib Superior to Ibrutinib in Patients with Relapsed or Refractory CLL/SLL
Patricia Stewart
TOP - January 2023 Vol 16, No 1 published on January 10, 2023 in ASH 2022 Highlights
Last modified: March 21, 2023